PROJECT STRANDSHIFT

HTT–Neuroimmune–Viragenesis Convergence Program

Document Code: SCF-AMC-STRANDSHIFT-DIR-0001

Program: PROJECT STRANDSHIFT

Research Classification: Advanced Disease Intelligence & Origin Discovery

Phase: Phase 0 — Disease Intelligence

1. EXECUTIVE SUMMARY

PROJECT STRANDSHIFT investigates the convergence of:

• HTT genomic instability
• DNA repair dysfunction
• Neuroimmune activation
• Neurodegeneration
• Autoimmune signaling
• Endogenous retroviral activation
• Viral mimicry biology
• Apoptosis
• Mitochondrial dysfunction
• Oncogenic remodeling pathways

using an integrated SCF multi-omic systems framework.

The objective is to determine whether shared biological mechanisms exist between Huntington disease pathogenesis, immune dysregulation, DNA injury responses, endogenous retroelement activation, and viral-response pathways.

The program does not assume that damaged human genes become viruses. Instead, it evaluates whether disease-associated DNA injury can induce biological states that resemble antiviral responses or activate endogenous retroviral elements.

2. DISEASE INTELLIGENCE SCOPE

Primary Disease Focus

Huntington Disease (HD)

Gene:

• HTT

Chromosomal Location:

• 4p16.3

Pathogenic Mechanism:

• Expanded CAG repeat tract
• Polyglutamine toxicity
• Somatic repeat expansion
• Protein misfolding
• Transcriptional dysregulation
• Neurodegeneration

Target Tissue:

Primary:

• Striatum

Secondary:

• Cortex
• Thalamus
• Cerebellum
• White matter
• Peripheral immune system

3. SCIENTIFIC INTELLIGENCE DOMAINS

Domain A — Genomic Instability

Research Questions

• How does HTT expansion influence genomic stability?
• Which DNA repair pathways modify disease severity?
• Which repair genes accelerate somatic expansion?
• What DNA injury signatures emerge during progression?

Priority Targets

• HTT
• MSH3
• MSH2
• FAN1
• MLH1
• PMS1
• PMS2
• EXO1
• ATM
• ATR
• PARP1
• BRCA1
• BRCA2

Deliverable:

• Genomic Instability Atlas

Domain B — Neuroimmune Biology

Research Questions

• How does mutant huntingtin alter innate immunity?
• Which cytokine networks become dysregulated?
• What role does microglial activation play?
• How early does neuroimmune dysfunction emerge?

Priority Systems

• Microglia
• Astrocytes
• Complement system
• Interferon pathways
• NF-κB signaling

Key Biomarkers

• IL-1β
• IL-6
• TNF-α
• IFN-I
• CXCL10
• CCL2

Deliverable:

• Neuroimmune Convergence Atlas

Domain C — Viragenesis & Viral Mimicry

Research Questions

• Can HTT-associated DNA damage activate endogenous retroelements?
• Does repeat instability trigger antiviral signaling?
• Does viral mimicry contribute to neurodegeneration?
• Are latent viral infections enriched in disease tissues?

Scientific Focus

Exogenous Viruses:

• Herpesviridae
• EBV
• CMV
• HHV-6
• HSV-1
• HSV-2

Endogenous Elements:

• HERV-K
• HERV-W
• LINE-1
• SINE elements

Deliverable:

• Viragenesis Intelligence Map

Domain D — Apoptosis & Cell Fate

Research Questions

• What thresholds trigger neuronal apoptosis?
• How does DNA damage influence cell fate?
• Which apoptotic pathways dominate disease progression?

Targets

• TP53
• BAX
• BCL2
• CASP3
• CASP7
• CASP9

Deliverable:

• Cell Fate Architecture Atlas

Domain E — Neurodevelopmental Vulnerability

Research Questions

• Do developmental trajectories influence disease onset?
• What role does early-life programming play?
• Which resilience factors delay progression?

Domains

• Synaptic development
• Neural plasticity
• Cognitive reserve
• Stress adaptation

Deliverable:

• Neurodevelopmental Vulnerability Framework

Domain F — Autoimmune Convergence

Research Questions

• Do autoimmune pathways overlap with HD biology?
• Are interferon signatures shared?
• Is molecular mimicry involved?

Targets

• HLA loci
• STAT1
• STAT3
• IRF family
• JAK-STAT signaling

Deliverable:

• Autoimmune Convergence Atlas

Domain G — Mitochondrial Biology

Research Questions

• How does mutant HTT alter bioenergetics?
• What role does mitochondrial dysfunction play?
• Does metabolic collapse precede symptoms?

Targets

• PGC1α
• TFAM
• OXPHOS complexes
• mtDNA integrity

Deliverable:

• Mitochondrial Failure Atlas

Domain H — Oncologic Remodeling

Research Questions

• Are angiogenic programs activated in diseased tissue?
• Do DNA repair defects share features with cancer biology?
• Can repair-remodeling transitions be quantified?

Targets

• VEGF
• HIF-1α
• MMP family
• TGF-β

Deliverable:

• Angiogenic Remodeling Atlas

4. MASTER RESEARCH HYPOTHESES

Hypothesis 1

HTT instability drives progressive genome instability through interactions with DNA repair pathways.

Hypothesis 2

DNA damage responses contribute to chronic neuroimmune activation.

Hypothesis 3

Endogenous retroelement activation may occur secondary to genomic instability and inflammatory signaling.

Hypothesis 4

Viral mimicry pathways contribute to disease progression independent of active infection.

Hypothesis 5

Shared molecular architectures exist between neurodegeneration, immune dysregulation, and genome-maintenance failure.

Hypothesis 6

Disease progression results from multi-system convergence rather than a single molecular defect.

5. TARGET TISSUE PRIORITIZATION

Tier 1

• Caudate nucleus
• Putamen
• Frontal cortex

Tier 2

• Motor cortex
• Hippocampus
• Cerebellum

Tier 3

• Peripheral blood
• CSF
• Lymphocytes
• Monocytes

Tier 4

• iPSC-derived neurons
• Brain organoids

6. PHASE 0 MANDATORY OUTPUTS

1. Disease Intelligence Report
2. Disease-Origin Intelligence Map
3. HTT Biological Systems Atlas
4. Neuroimmune Intelligence Atlas
5. Viragenesis Intelligence Map
6. Autoimmune Convergence Atlas
7. DNA Repair Intelligence Atlas
8. Mitochondrial Biology Atlas
9. Oncologic Remodeling Atlas
10. SCF Disease Intelligence Blueprint

7. PHASE 0 SUCCESS CRITERIA

Completion requires:

• Disease boundaries established
• Biological systems mapped
• Tissue hierarchy defined
• Molecular targets prioritized
• Assay strategy defined
• Translational endpoints established
• Phase 1 discovery pathway approved

CONCLUSION

PROJECT STRANDSHIFT establishes a comprehensive SCF disease-intelligence framework to investigate the convergence of HTT instability, DNA repair dysfunction, neuroimmune signaling, endogenous retroelement activation, viral-response biology, apoptosis, and neurodegenerative progression. The output of Phase 0 serves as the foundational intelligence layer supporting all subsequent discovery, pathogenesis, biomarker, and therapeutic-engineering phases.

MASTER REGISTRY INDEX

SCF-AMC-STRANDSHIFT-0001 — PROJECT STRANDSHIFT

SCF-AMC-STRANDSHIFT-DIR-0001 — Disease Intelligence Report

SCF-AMC-STRANDSHIFT-GIA-0001 — Genomic Instability Atlas

SCF-AMC-STRANDSHIFT-NIA-0001 — Neuroimmune Intelligence Atlas

SCF-AMC-STRANDSHIFT-VIM-0001 — Viragenesis Intelligence Map

SCF-AMC-STRANDSHIFT-ACA-0001 — Autoimmune Convergence Atlas

SCF-AMC-STRANDSHIFT-MFA-0001 — Mitochondrial Failure Atlas

SCF-AMC-STRANDSHIFT-ARA-0001 — Angiogenic Remodeling Atlas

SCF-DMRD-MASTER-0001 — SCF Advanced Disease Modeling & Discovery

SCF-PATH-UT-0001 — SCF Pathophysiology Protocol

This document fully defines the HTT–neuroimmune–viral research scope required for Phase 0 and establishes the scientific boundaries, target systems, hypotheses, tissues, and downstream deliverables for PROJECT STRANDSHIFT.